Leaflet JELIGO 5mg film-coated tablets

Product code:
W70821001
Quantity:
30
Indicated for:
type 2 diabetes mellitus
Route of administration:
oral
Substance:
linagliptin (DPP-4 inhibitor)
ATC
A10BH05 — Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Dipeptidyl peptidase 4 (DDP-4) inhibitors
Linagliptin is a medication used to treat type 2 diabetes. It belongs to the class of DPP-4 inhibitors (dipeptidyl peptidase-4) and helps lower blood sugar levels by increasing insulin secretion and reducing glucagon production.

The medication is taken orally, usually once daily, and can be used alone or in combination with other antidiabetic medications. It is important for patients to follow a balanced diet and engage in regular physical activity to maximize the benefits of treatment.

Side effects may include upper respiratory tract infections, headaches, or allergic reactions. In rare cases, pancreatitis or hypoglycemia may occur, especially when linagliptin is used with other blood sugar-lowering medications.

Patients should inform their doctor about any other medications they are taking and strictly follow the administration instructions. Pregnant or breastfeeding women should consult a specialist before using this medication.

General data about JELIGO 5mg

Substance:
linagliptin
Date of latest medicines list:
01-02-2025
Product code:
W70821001
Concentration:
5mg
Pharmaceutical form:
film-coated tablets
Quantity:
30
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
GENEPHARM S.A. - GRECIA
Holder:
EGIS PHARMACEUTICALS PLC. - UNGARIA
Number:
15753/2024/01
Shelf life:
30 months

Pharmaceutical forms available for linagliptin

Combinations with other substances